Company intelligence / Profile preview
Pikralida
Poznań, Polandpikralida.eu ↗
- Ownership
- Private
- Employees
- ~26
- Development stage
- Preclinical
01
Overview
Pikralida’s lead human programs—TRX‑03 for poststroke neuroprotection and TRX‑06 for oral snakebite antivenom—have both completed Phase I clinical trials in healthy volunteers. The veterinary antivenom program, TRX‑12, has finished toxicology studies in dogs with formulation work ongoing. The company’s flagship project PKL‑021 targets MMPs but its clinical stage was not explicitly stated.[1][2][3]
- Therapeutic areas
- OtherNeurology
- Modalities
- Small molecules[4]Combination drugs/formulations[4]Modern drug delivery systems[4]
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
Not specifically listed; provides CRO services to national/international pharma companies across Europe/USA including large corporations and SMEs since 2019.[3]
Beyond the preview
Go deeper on Pikralida.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Pikralida.